Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
The thought of breast cancer can send shivers down your spine. It is a rather common form of cancer, which can lead to many complications and adverse effects. Moreover, it can affect women at any age, and sometimes it can affect teens. There are no definite causes of breast cancer in teens. However....
If a diagnosis of breast cancer has brought your world to a crashing halt, you're not alone. You need to be in the best shape possible - emotionally, physically and mentally - as you navigate life as a breast cancer patient. That's why self-care is crucial as a source of sustenance and strength, and....
Yes...There are many stories with happy ending. Chemo is not the end of your life. Every day is a gift... that's what chemo reminds you. The majority of women who develop breast cancer around the world will not die of breast cancer. In fact, 8 out of 10 women who are diagnosed with breast cancer wil....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
எழுதியவர்:Dr. Nitika Sharma - BDS
மதிப்பிட்டவர்:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.